Antibody-dependent cellular cytotoxicity in HIV infections - PubMed (original) (raw)
Review
Antibody-dependent cellular cytotoxicity in HIV infections
A Ahmad et al. FASEB J. 1996 Feb.
Abstract
ADCC is an important immune effector mechanism against tumor and virus-infected cells that can be destroyed by the combined action of specific antibodies of IgG isotype against cell surface-associated antigens and effector cells, predominantly of the NK phenotype. ADCC has been shown to function in vivo in several systems. With regard to HIV, it can be readily demonstrated in vitro against the viral envelope proteins with serum and/or effector cells obtained from HIV-infected subjects. Several studies have demonstrated that the titers of the envy-specific ADCC-mediating antibodies decrease in the sera of HIV-infected individuals as the infection progresses toward AIDS. The cells that mediate ADCC also become functionally compromised in these individuals in early stages of the infection, thus depriving the host of the potential benefits of this process. Restoration of this process in the infected individuals by the administration of functionally competent effector cells (in vitro expanded and lymphokine-activated killer cells) and ADCC-mediating antibodies (hyperimmune serum or appropriate monoclonal antibodies), alone or in combination, may help slow the disease progress. Because of the multicomponent nature of the process, ADCC-mediating antibodies may prove a better correlate of protection and prognosis than the virus-specific neutralizing antibodies and cytotoxic T cells in assessing anti-HIV immunization and immunotherapy.
Similar articles
- Positive correlation between the natural killer and gp 120/41-specific antibody-dependent cellular cytotoxic effector functions in HIV-infected individuals.
Ahmad A, Menezes J. Ahmad A, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Oct 1;10(2):115-9. doi: 10.1097/00042560-199510020-00002. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7552474 - Antibody-Dependent Cellular Cytotoxicity Activity of Effector Cells from HIV-Infected Elite and Viral Controllers.
Isitman G, Lisovsky I, Tremblay-McLean A, Kovacs C, Harris M, Routy JP, Bruneau J, Wainberg MA, Tremblay C, Bernard NF. Isitman G, et al. AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):1079-1088. doi: 10.1089/AID.2016.0157. Epub 2016 Sep 7. AIDS Res Hum Retroviruses. 2016. PMID: 27499379 - Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses.
Wren LH, Stratov I, Kent SJ, Parsons MS. Wren LH, et al. Vaccine. 2013 Nov 12;31(47):5506-17. doi: 10.1016/j.vaccine.2013.08.035. Epub 2013 Aug 24. Vaccine. 2013. PMID: 23981432 Review. - Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity.
Bernard NF, Kiani Z, Tremblay-McLean A, Kant SA, Leeks CE, Dupuy FP. Bernard NF, et al. Front Immunol. 2017 Aug 24;8:1033. doi: 10.3389/fimmu.2017.01033. eCollection 2017. Front Immunol. 2017. PMID: 28883824 Free PMC article. Review.
Cited by
- Mapping the interplay between NK cells and HIV: therapeutic implications.
Anderko RR, Mailliard RB. Anderko RR, et al. J Leukoc Biol. 2023 Feb 1;113(2):109-138. doi: 10.1093/jleuko/qiac007. J Leukoc Biol. 2023. PMID: 36822173 Free PMC article. Review. - The HIV Env Glycoprotein Conformational States on Cells and Viruses.
Zhao C, Li H, Swartz TH, Chen BK. Zhao C, et al. mBio. 2022 Apr 26;13(2):e0182521. doi: 10.1128/mbio.01825-21. Epub 2022 Mar 24. mBio. 2022. PMID: 35323042 Free PMC article. Review. - Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19.
Jeyaraman M, Muthu S, Bapat A, Jain R, Sushmitha ES, Gulati A, Channaiah Anudeep T, Dilip SJ, Jha NK, Kumar D, Kesari KK, Ojha S, Dholpuria S, Gupta G, Dureja H, Chellappan DK, Singh SK, Dua K, Jha SK. Jeyaraman M, et al. Heliyon. 2021 Jul;7(7):e07635. doi: 10.1016/j.heliyon.2021.e07635. Epub 2021 Jul 21. Heliyon. 2021. PMID: 34312598 Free PMC article. Review. - Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies.
Parsons MS, Chung AW, Kent SJ. Parsons MS, et al. Retrovirology. 2018 Aug 22;15(1):58. doi: 10.1186/s12977-018-0438-x. Retrovirology. 2018. PMID: 30134945 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical